AbbVie, Schizophrenia and Phase II

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
Key Takeaways Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.Abbvie said the trials did not show a statistically significant improvement in symptoms compared with the placebo group at week 6.
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
"AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general ...
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.
AbbVie shares tumble after schizophrenia drug disappoints
US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial investigating emraclidine as a once-daily oral monotherapy treatment for adults with schizophrenia did not meet the primary endpoint of showing a “statistically significant” improvement when compared with a placebo group.
AbbVie under pressure as schizophrenia drug fails two trials
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, Bristol Myers’ BMY stock was up 10.
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
BioPharma Dive4d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Buy, Sell, Or Hold AbbVie Stock?
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
Business Insider3d
AbbVie Hold Rating Maintained Amid Emraclidine Trial Challenges and Competitive Pressure
David Risinger’s rating is based on several key considerations surrounding AbbVie’s recent clinical trial outcomes. The company’s announcement on November 11, 2024, revealed that emraclidine’s ...
BioPharma Dive4d
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
FierceBiotech4d
AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
Why AbbVie Stock Was Getting Mashed on Monday
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...
Seeking Alpha4d
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...